Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

NCT02739360 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Gilead Sciences